Loading
Egle Therapeutics is a Paris company developing medicines that act on regulatory T cells, the immune cells that can shield a tumour from attack. Its cancer drug, EGL-001, is designed to selectively inhibit these cells inside tumours and is in an early trial in advanced solid tumours.
Egle Therapeutics SAS, based in Paris, develops IL-2 variant immunoconjugates that modulate regulatory T cells (Tregs), using a proprietary discovery platform to find Treg-specific targets. In oncology its lead candidate EGL-001 is a Treg-selective anti-CTLA-4 antibody fused to a modified IL-2 (anti-CTLA4-IL-2m), designed to selectively inhibit Tregs in tumours; in autoimmunity EGL-003 is an IL-2 agonist Treg engager. Christophe Queva was appointed chief executive in January 2025, and the website now names John Celebi as chief executive. Its first registered cancer trial, NCT06622486, a first-in-human phase 1/2 study of EGL-001 in selected advanced or metastatic solid tumours at sites in France and Spain, was posted on ClinicalTrials.gov in October 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/